The CheckMate 026 trial compared the efficacy of nivolumab monotherapy to chemotherapy for the first-line treatment of patients with PD-L1-positive (≥1%) stage IV or recurrent NSCLC and showed that nivolumab did not result in a significant prolongation of survival versus chemotherapy in patients with PD-L1 expression levels of 5% or higher (32). The gene discussed is CD274; the disease is non-small cell lung carcinoma.